Business Development
Improve yields and abiotic stress with ATI.
Our business model involves co-development or licensing. Preferred partners are innovative seed companies who are dissatisfied with current approaches to yield improvement, biotic and abiotic stress tolerance or extended shelf life.
Revenues achieved through:
Development
-
ATI or its parent owns elite germplasm for improving yield, stress tolerance and/or shelf life, and introduces the improved varieties or hybrid parents directly into the marketplace.
-or-
Co-Development
-
Co-funding research, then sharing income on trait added value from sales of yield-enhanced, stress-tolerant seeds, and longer shelf life crops
-or-
Licensing
-
Upfront technology & research maintenance fees
-
Benchmark payments for proof of concept / commercial development
-
Recurring revenues from trailing royalties on commercialized products
Strategic Partnering
We boast a significant competitive advantage with domain technical, licensing and co-development experience, have dominant IP in plant yield genes with 16 issued US patents and foreign counterparts, and new applications for genome editing of our validated targets.
We are not aware of any direct competitors expressing commercially relevant yield genes in transgenic or genome edited plants with similar field trial data.
Most importantly, there are convincing laboratory, greenhouse and field trial demonstrations of broad applications to significantly improving crop yields with our technology, as well as secondary benefits in abiotic stress resistance, disease tolerance, and improved shelf life.
Co-development terms are negotiated by crop
Market Overview
With wide farmer adoption of genetically engineered crop plants, 457 million acres of all croplands have been planted to GM varieties in 26 countries (2016). In the US, over 93% of soy, cotton and corn are genetically modified. Additionally, over 18 million farmers in developing countries are growing 54% of worldwide GM crops. Over 20 major crop plants have been genetically engineered with improved traits, boosting worldwide commercial sales to exceed $15.7 Billion.
Agribody's genome editing via small and targeted mutations avoids concerns associated with GMOs, which reduces risk & costs, and speeds up commercialization
Market Stats:
-
Serviceable Available Market: $13 Bil.
-
Simply increasing alfalfa yields by 20% can boost seed value at a minimum of $50 million per year
Ref: ISAAA.org
Agribody Technologies, Inc.
12526 High Bluff Dr. #300
San Diego, CA 92130
© 2021 by Agribody Technologies, Inc.
We seek co-development opportunities and licensees with innovative seed companies in alfalfa, banana, beans, cannabis, canola, corn, cotton, flowers, grapes, lettuce, okra, peanut, peas, rice, sorghum, sugarbeet and other crops.
For crop-specific Licensing, we seek:
-
Technology Access & Research Maintenance Fees
-
Benchmark Payments
-
Royalties on product sales
Co-development
-
Lab / Greenhouse / Field Testing / Regulatory Services
-
Trait value added sales of yield-enhanced, stress-tolerant seeds
Licensing and Co-development terms are negotiated by crop.
Criteria for target crop selection for genome editing:
-
Fully sequenced genome of a reference variety in the target species; and
-
Genetic transformation protocol with routine tissue culture permitting high efficiency plant transformation.